Cart
sales@molnova.com
Zederone
CAS No. 7727-79-9
Zederone ( )
Catalog No. M31299 CAS No. 7727-79-9
Zederone has anti-bacterial activity,it inhibits gram-positive bacteria activity. Zederone induces hepatotoxicity implicated the induction of Cyps, which leads to the formation of biological reactive metabolites and that cause the oxidative stress and liver cell injuries.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 381 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameZederone
-
NoteResearch use only, not for human use.
-
Brief DescriptionZederone has anti-bacterial activity,it inhibits gram-positive bacteria activity. Zederone induces hepatotoxicity implicated the induction of Cyps, which leads to the formation of biological reactive metabolites and that cause the oxidative stress and liver cell injuries.
-
DescriptionZederone has anti-bacterial activity,it inhibits gram-positive bacteria activity. Zederone induces hepatotoxicity implicated the induction of Cyps, which leads to the formation of biological reactive metabolites and that cause the oxidative stress and liver cell injuries.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number7727-79-9
-
Formula Weight246.3
-
Molecular FormulaC15H18O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
4-Nitroquinoline 1-o...
4-Nitroquinoline 1-oxide is a highly carcinogenic modeling compound that induces mutations in bacteria, fungi and animals by forming numerous purine adducts.
-
Dehydrocostus Lacton...
Dehydrocostus Lactone is a major sesquiterpene lactone isolated from the roots of Saussurea lappa.
-
Isosilybin
Isosilybin and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.
